Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma

Keyphrases

• Peripheral T-cell Lymphoma 100%
• Cutaneous T-cell Lymphoma 100%
• Brentuximab Vedotin 100%
• Relapsed or Refractory 44%
• Therapeutic Advances 22%
• CD30 Positive 22%
• Adverse Effects 11%
• Randomized Trial 11%
• Progression-free Survival 11%
• Monotherapy 11%
• Clinically Significant 11%
• Consolidation Therapy 11%
• Overall Survival 11%
• Peripheral Neuropathy 11%
• Phase II Study 11%
• Durable Response 11%
• T-cell Lymphoma 11%
• Antibody-drug Conjugate 11%
• Anaplastic Large Cell Lymphoma 11%
• Predictive Biomarker 11%
• CD30 11%
• Frontline Therapy 11%
• Overall Survival Benefit 11%
• CD30 Expression 11%

Medicine and Dentistry

• Peripheral T-Cell Lymphoma 100%
• Cutaneous T Cell Lymphoma 100%
• Brentuximab Vedotin 100%
• Overall Survival 22%
• Biological Marker 11%
• Adverse Event 11%
• Monotherapy 11%
• Progression Free Survival 11%
• Neuropathy 11%
• Antibody-Drug Conjugate 11%
• T-Cell Lymphoma 11%
• Anaplastic Large Cell Lymphoma 11%
• CHOP 11%

Pharmacology, Toxicology and Pharmaceutical Science

• Peripheral T Cell Lymphoma 100%
• Brentuximab Vedotin 100%
• Cutaneous T Cell Lymphoma 100%
• Overall Survival 22%
• Progression Free Survival 11%
• Monotherapy 11%
• Adverse Event 11%
• Biological Marker 11%
• Neuropathy 11%
• T Cell Lymphoma 11%
• Antibody Drug Conjugate 11%
• Anaplastic Large Cell Lymphoma 11%